PAH News

May 23, 2019May 23, 2019

Uptravi Beneficial Regardless of When Started, But More Effective if Started Early, Analysis Suggests

News, PAH News

A new analysis of Actelion‘s GRIPHON clinical trial indicates that Uptravi (selexipag) tablets reduce the risk of disease complications or death in patients with pulmonary arterial hypertension (PAH), regardless of ... Read more

May 20, 2019May 20, 2019

Resverlogix Announces Promising Findings on Apabetalone, Will Launch Phase 2 Trial in PAH Patients

News, PAH News

Promising preclinical findings recently published in a peer-reviewed journal opened the door to the launch of a Phase 2 trial testing the therapeutic potential of apabetalone (RVX-208), Resverlogix‘s proprietary ... Read more

May 6, 2019May 6, 2019

Teva Launches Generic Version of PAH Therapy Letairis in US

News, PAH News

Teva Pharmaceutical Industries launched a generic version of Letairis (ambrisentan) in the United States for the treatment of pulmonary arterial hypertension. Generic ambrisentan will be available as 5 and ... Read more

May 2, 2019May 16, 2019

FDA Approves Abbreviated New Drug Application for Cipla’s Ambrisentan Generic Tablets for PAH Treatment

News, PAH News

The U.S. Food and Drug Administration (FDA) has approved the abbreviated new drug application (ANDA) for Cipla‘s ambrisentan generic tablets of 5 and 10 mg. These tablets are a generic ... Read more

April 29, 2019April 30, 2019

Poor Heart Function Raises Risk of Early Death After Lung Transplant for IPAH Patients, Study Suggests

News, PAH News

Certain parameters of poor heart function are risk factors for early death among idiopathic pulmonary arterial hypertension (IPAH) patients who undergo lung transplant, a small Chinese study suggests. The ... Read more

April 24, 2019April 24, 2019

NT-proBNP Levels Can Predict Long-term Outcomes and Treatment Response in PAH Patients, Study Says

News, PAH News

Levels of NT-proBNP can predict long-term outcomes and response to treatment with Uptravi (selexipag) in patients with pulmonary arterial hypertension (PAH), a post-hoc analysis of the Phase 3 GRIPHON trial shows. ... Read more

April 22, 2019April 22, 2019

Survival Rates for Lung Disease-associated PH Similar to Poor Survival in IPH, Study Suggests

News, PAH News, PH News

Despite having better heart function and less severe disease, patients with a lung disease underlying their pulmonary hypertension (PH) have survival rates that are as poor as those with ... Read more

April 18, 2019April 18, 2019

Heart’s Ventricular Mass on MRI May Predict Risk of Death in PAH, Study Says

News, PAH News

The heart’s ventricular mass may be an early prognostic biomarker for predicting the risk of heart failure and death in people with pulmonary arterial hypertension (PAH), a recent study suggests. ... Read more

April 11, 2019April 11, 2019

United Therapeutics Ends Clinical Development of Esuberaprost as Add-on Therapy for PAH

News, PAH News

United Therapeutics announced it has ended its Phase 3 BEAT trial testing esuberaprost as an add-on therapy to its product Tyvaso (inhaled treprostinil) for clinically symptomatic patients with pulmonary arterial hypertension (PAH). According ... Read more

April 5, 2019April 5, 2019

LRP1 Protein Levels Linked to Blood Vessel Remodeling in PH, Study Suggests

News, PAH News, PH News

Increased levels of a protein called LRP1 may lead to blood vessel remodeling in pulmonary hypertension (PH) by causing changes in pulmonary artery cells that favor their proliferation, a ... Read more

Pin It on Pinterest